Your browser doesn't support javascript.
loading
Development of a calculated panel reactive antibody calculator for the United Arab Emirates: a proof of concept study.
Alvares, Marion; Anwar, Siddiq; Hashmi, Shahrukh K; Zaman, Muhammad Badar; Al Mahri, Ayeda; Alvares, Christabelle; Al Katheeri, Layla; Purushothaman, Ananthanayagi; Ralonya, Mesele Emily; Sangalang, Marie Glo; Jannang, Raysha; Abdulle, Abdulkadir; Al Qubaisi, Alyazia; Al Ahmed, Maitha; Khamis, Amar Hassan; Al Seiari, Mohamed; Al Obaidli, Ali; Al Yafei, Zain; ElGhazali, Gehad.
Afiliação
  • Alvares M; Transplant Immunology section, Sheikh Khalifa Medical City, Union71 - Purehealth, Abu Dhabi and College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.
  • Anwar S; Department of Medicine, Sheikh Shakbout Medical City, Abu Dhabi, United Arab Emirates.
  • Hashmi SK; Department of Medicine, Sheikh Shakbout Medical City, Abu Dhabi, United Arab Emirates.
  • Zaman MB; Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
  • Al Mahri A; Clinical Affairs, Khalifa University, Abu Dhabi, United Arab Emirates.
  • Alvares C; Renal Transplant Department, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates.
  • Al Katheeri L; Transplant Immunology section, Sheikh Khalifa Medical City, Union71 - Purehealth, Abu Dhabi and College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.
  • Purushothaman A; Rochester Institute of Technology, New York, USA.
  • Ralonya ME; Transplant Immunology section, Sheikh Khalifa Medical City, Union71 - Purehealth, Abu Dhabi and College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.
  • Sangalang MG; Department of Medicine, Sheikh Shakbout Medical City, Abu Dhabi, United Arab Emirates.
  • Jannang R; Renal Transplant Department, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates.
  • Abdulle A; Transplant Immunology section, Sheikh Khalifa Medical City, Union71 - Purehealth, Abu Dhabi and College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.
  • Al Qubaisi A; Transplant Immunology section, Sheikh Khalifa Medical City, Union71 - Purehealth, Abu Dhabi and College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.
  • Al Ahmed M; Transplant Immunology section, Sheikh Khalifa Medical City, Union71 - Purehealth, Abu Dhabi and College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.
  • Khamis AH; Transplant Immunology section, Sheikh Khalifa Medical City, Union71 - Purehealth, Abu Dhabi and College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.
  • Al Seiari M; Renal Transplant Department, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates.
  • Al Obaidli A; Mohamed Bin Rashed University of Medicine and Medical Sciences, Dubai, United Arab Emirates.
  • Al Yafei Z; Renal Transplant Department, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates.
  • ElGhazali G; SEHA Kidney Care, Abu Dhabi, United Arab Emirates.
Sci Rep ; 13(1): 8468, 2023 05 25.
Article em En | MEDLINE | ID: mdl-37231090
ABSTRACT
Calculated panel reactive antibody (CPRA) is used to help increase sensitized patient's access to transplantation. United Arab Emirates (UAE) has a diverse resident population hence we developed a UAE-CPRA calculator based on HLA antigen frequencies of the different ethnic groups that represent the UAE population. HLA antigen frequencies at serological split antigen level for HLA-A, -B, -C, -DRB1 and -DQB1 of 1002 healthy unrelated donors were performed. We subsequently compared the performance of the UAE CPRA calculator with the Organ Procurement and Transplantation Network (OPTN) and the Canadian CPRA calculators in 110 Kidney Transplant waitlist patients from January 2016 to December 2018. Lin's concordance correlation coefficient showed a moderate agreement between the UAE and OPTN calculator (Rc = 0.949, 95% CI 0.929-0.963) and the UAE and Canadian calculators (Rc = 0.952, 95% CI 0.932-0.965). While there continued to be a moderate agreement (Rc = 0.937, UAE versus OPTN calculator) in the lower sensitized group, a poor agreement (Rc = 0.555, UAE versus OPTN calculator) was observed in the higher sensitized group. In this study, we provide a template for countries to develop their own population-specific CPRA calculator. Implementation of the CPRA algorithm based on HLA frequencies of the multi-ethnic UAE population will be more fitting to increase access to transplantation and improve transplant outcomes. Our study demonstrates that the CPRA calculators developed using the data from the western population had poor correlation in our higher sensitized patients disadvantaging them in potential organ allocations systems. We plan to further refine this calculator by using high resolution HLA typing to address the problem of a genetically diverse population.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Rim Limite: Humans País como assunto: America do norte / Asia Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Rim Limite: Humans País como assunto: America do norte / Asia Idioma: En Ano de publicação: 2023 Tipo de documento: Article